Project Grant R44HL152835
- Federal Grant Award Summary Cutcath LLC received a $395,306 Small Business Technology Transfer (STTR) Phase I project grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 15, 2025, with completion targeted for December 31, 2026. The company is developing and testing the Cutcath Dissection Septum Cutting Catheter (DSCC), a novel minimally invasive electrosurgical device designed to address acute aortic...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $413,595 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Unandup, LLC, a St. Louis-based technology development firm, to fund the development of a Magnetic Rotational Platform for Coronary Lesions. The project aims to address the significant clinical challenges associated with percutaneous coronary intervention (PCI) procedures, particularly in navigating tortuous vessels and enabling stent...
- Federal Grant Award Summary Nimble Surgical Incorporated received a $314,362 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, through September 14, 2026. The company will develop and advance the FLEXLOCK guide catheter, a manually operable medical device featuring an innovative anchoring tip designed to provide simultaneous active and passive support for complex...
- Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...
- This $437,461 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel stabilization catheter device for His pacing lead implantation. The goal is to improve the accuracy and ease of His bundle pacing, an emerging alternative cardiac resynchronization therapy (CRT) for heart failure patients. The project aims to refine a deployable suction-tipped lead...
- Federal Project Grant Award Summary Aust Development, LLC received a $313,302 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), with an award date of September 15, 2025 and completion target of August 31, 2026. The company will develop and deliver a novel precision lead delivery platform designed to improve cardiac conduction system (CCS) pacing procedures. The deliverables include a...
- Federal Project Grant Award Summary Link Medical LLC received a $596,736 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on July 1, 2025, with completion anticipated by December 31, 2026. The award supports Phase I development of a novel catheter-based device designed to treat mitral valve regurgitation, a condition expected to affect approximately four million Americans by 2030. Link Medical's...
- Federal Grant Award Summary Coridea, LLC received a $982,086 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025 through August 31, 2027. The award funds development and validation of a novel, minimally invasive cervical surgical approach to phrenic nerve stimulation for treating central sleep apnea (CSA). This research addresses a critical clinical gap: while phrenic nerve...
- Corveus Medical, Inc. was awarded a $255,841 Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop an extravascular bipolar catheter for targeted nerve ablation with minimal collateral damage to surrounding tissues. The grant aims to support the design and prototyping of a minimally invasive, catheter-delivered venous procedure for performing extravascular greater splanchnic nerve ablation. The proposed catheter...
- This $256,000 National Science Foundation project grant supports the development of an automated chest tube to prevent clotting. Circulatech LLC will design and prototype a novel chest tube that proactively manages fluid flow within the catheter lumen to flush and drain the tube, reducing blood clot formation. Through a process called "dilutional coagulopathy," the tube will use sterile saline or anticoagulants to reduce thrombosis in the drainage space rather than relying on...
CATHETER FOR COMPLEX PERCUTANEOUS CORONARY INTERVENTION - ABSTRACT NEARLY 1 MILLION PERCUTANEOUS CORONARY INTERVENTIONS (PCIS) ARE PERFORMED EACH YEAR IN THE US. APPROXIMATELY 70% OF THESE CASES ARE CONSIDERED COMPLEX AND REQUIRE THE TREATMENT OF CALCIFIED LESIONS, TORTUOUS VESSELS, AND MULTI-VESSEL DISEASE, OFTEN WITH TOTAL OR SUB-TOTALLY OCCLUDED LESIONS. MANY OPERATORS AVOID THESE MORE COMPLEX CASES, WHICH ARE OFTEN NOT SUITABLE FOR RADIAL ACCESS APPROACHES DUE TO THE LIMITATIONS OF SMALLER SIZE GUIDE CATHETERS AND LACK OF SUPPORT REQUIRED TO EFFECTIVELY DELIVER CORONARY STENTS AND OTHER INTERVENTIONAL DEVICES. TO OVERCOME THIS LIMITATION, GUIDE EXTENSION CATHETERS (GEC) HAVE BEEN DEVELOPED TO HELP DELIVER STENTS IN THESE CHALLENGING ANATOMIES. GECS ARE CURRENTLY UTILIZED IN APPROXIMATELY 18% OF ALL CORONARY INTERVENTIONS. HOWEVER, GECS HAVE SEVERAL KEY SHORTCOMINGS THAT HAVE PREVENTED THEIR USAGE OTHER THAN AS A BAILOUT OPTION. SPECIFICALLY, CURRENT GECS ARE UNABLE TO ACCESS MORE DISTAL TORTUOUS LESIONS IN 28% OF CASES, RESULTING IN THE INABILITY TO DELIVER A STENT IN MANY CASES. BLUNT ENDED TUBULAR GECS ALSO HAVE SERIOUS SAFETY ISSUES WITH CORONARY ARTERY DISSECTION AND/OR PLAQUE OR THROMBUS EMBOLIZATION. GIVEN THAT GECS ARE USED IN ~18% OF ALL PCI CASES, THESE DATA REPRESENT A SIGNIFICANT VOLUME OF PATIENTS THAT ARE NOT TREATED EFFECTIVELY. HENCE, CROSSLINER INC. HAS DEVELOPED A NOVEL MULTI-FUNCTIONAL GEC THAT COMBINES THE REQUIREMENT FOR DEEPER CATHETER INTUBATION WITH A MICROCATHETER LEADING TIP, AND PRE-DILATATION BALLOON ON THE LEADING ELEMENT, TO ALLOW SAFE CROSSING OF SEVERE LESIONS IN TORTUOUS CORONARY VESSELS, WITH BALLOON PRE-DILATATION, FOLLOWED BY CROSSING THE LESION WITH THE GUIDE EXTENSION AND THEN SEAMLESS STENT DELIVERY. THE COMBINATION OF A GEC WITH A SEAMLESS TRANSITION FROM THE OUTER TO THE INNER MICROCATHETER-BALLOON PROVIDES THE CAPABILITY FOR EASIER STENT DELIVERY, WHICH CAN BE UNSHEATHED AT THE LESION AS OPPOSED TO BEING DELIVERED FROM A POORLY SUPPORTED PROXIMAL LOCATION. THIS APPROACH ENABLED BY THE CROSSLINER GEC WILL SUBSTANTIALLY IMPROVE PCI IN PATIENTS WITH COMPLEX LESIONS WHILE REDUCING RISKS, PROCEDURAL DURATION, RADIATION/CONTRAST EXPOSURE, STENT DISLODGEMENT, CORONARY DISSECTION AND PERFORATION THAT EXIST WITH CURRENT GECS. DATA FROM BENCH AND IN VIVO PHASE I STUDIES SUPPORT THE UTILITY OF CROSSLINER'S MULTI-FUNCTIONAL GEC BY DEMONSTRATING A SIGNIFICANT REDUCTION IN THE FORCE REQUIRED TO PASS A HIGHLY ANGULATED SEGMENT WHILE INCREASING THE INTUBATION DEPTH COMPARED TO FIRST-GENERATION DEVICES. RESULTS IN VIVO SHOWED AN INCREASE IN INTUBATION DEPTH FROM 5.6 CM TO 12.9 CM AND A 41% REDUCTION IN THE TIME TO DELIVER A STENT. IMPORTANTLY, THE CROSSLINER GEC WAS ABLE TO SUCCESSFULLY CROSS STENTED SEGMENTS IN ALL VESSELS IN A SWINE MODEL OF COMPLEX LESIONS, WHILE FIRST-GENERATION DEVICES WERE STUCK PROXIMAL TO THE STENT OR AT THE STENT EDGE IN ~75% OF THE CORONARY VESSELS TESTED. THE CROSSLINER SYSTEM IS NOW READY FOR FINAL PROCESS REFINEMENT AND DESIGN CONTROL DEVELOPMENT (AIM 1) FOLLOWED BY USABILITY EVALUATION, AND REGULATORY CLEARANCE (AIM 2). SUCCESSFUL EXECUTION OF THESE PHASE II STUDIES WILL POSITION THE CROSSLINER GEC SYSTEM FOR FULL COMMERCIALIZATION OF THIS HIGHLY INNOVATIVE APPROACH TO IMPROVE THE TREATMENT FOR COMPLEX PCI PATIENTS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | ($5k) | 1/30/25 | ||
| Not listed | $5.3k | 1/30/25 | ||
| Not listed | $0 | 1/30/25 | ||
| Not listed | $990.6k | 1/17/25 | ||
| Not listed | $990.6k | 1/17/25 |